Scott R Plotkin Selected Research

Schwannomatosis

1/2022	Genetic testing to gain diagnostic clarity in neurofibromatosis type 2 and schwannomatosis.
1/2022	Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation.
11/2021	Identifying challenges in neurofibromatosis: a modified Delphi procedure.
8/2018	Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis.
8/2016	Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.
8/2016	Current status and recommendations for biomarkers and biobanking in neurofibromatosis.
1/2016	Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.
3/2014	CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
3/2013	Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.
12/2012	Expression of SMARCB1 (INI1) mutations in familial schwannomatosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Scott R Plotkin Research Topics

Disease

46	Neoplasms (Cancer) 01/2022 - 02/2003
21	Neurofibromatosis 2 (Neurofibromatosis Type II) 01/2022 - 05/2009
16	Acoustic Neuroma (Acoustic Neurinoma) 01/2022 - 10/2005
14	Neurofibromatoses (Neurofibromatosis) 01/2021 - 05/2010
13	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 06/2010
13	Neurilemmoma (Schwannoma) 01/2021 - 07/2009
12	Meningioma (Meningiomas) 11/2021 - 02/2008
10	Schwannomatosis 01/2022 - 12/2012
7	Neurofibromatosis 1 (Neurofibromatosis Type I) 11/2021 - 02/2013
5	Pain (Aches) 11/2021 - 09/2012
5	Hearing Loss (Hearing Impairment) 01/2021 - 11/2015
4	Plexiform Neurofibroma 11/2021 - 01/2020
4	Edema (Dropsy) 01/2021 - 11/2015
3	Lymphoma (Lymphomas) 01/2022 - 09/2004
3	Carcinogenesis 01/2018 - 11/2007
2	Glioma (Gliomas) 11/2021 - 01/2020
2	Neurofibrosarcoma (MPNST) 11/2021 - 03/2015
2	Hypertension (High Blood Pressure) 01/2021 - 10/2016
2	Neurofibroma 10/2018 - 10/2005
2	Necrosis 03/2011 - 01/2011
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022
1	Fatigue 01/2021
1	Fibrosis (Cirrhosis) 01/2021
1	Hypothyroidism 01/2021
1	Leukemia 01/2021
1	Pseudarthrosis (Pseudoarthrosis) 01/2021
1	Nervous System Neoplasms (Neoplasms, Nervous System) 01/2018
1	Tinnitus 01/2018
1	Thrombocytopenic Purpura (Thrombopenic Purpura) 10/2016
1	Apnea 08/2016
1	Muscular Atrophy (Muscle Atrophy) 11/2015

Drug/Important Bio-Agent (IBA)

11	Bevacizumab (Avastin)FDA Link 01/2020 - 07/2009
10	Biomarkers (Surrogate Marker)IBA 12/2019 - 06/2011
9	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018 - 10/2005
7	Uvitex SWN (SWN)IBA 01/2022 - 01/2016
7	Temozolomide (Temodar)FDA LinkGeneric 01/2020 - 06/2011
6	Pharmaceutical PreparationsIBA 11/2021 - 01/2018
4	Oxygen (Dioxygen)IBA 01/2021 - 06/2011
4	Mechanistic Target of Rapamycin Complex 1IBA 01/2021 - 08/2009
4	Biological ProductsIBA 01/2021 - 02/2003
4	cediranib (AZD2171)IBA 01/2017 - 06/2010
3	Phosphotransferases (Kinase)IBA 01/2021 - 07/2015
3	Neurofibromin 2 (Merlin)IBA 01/2018 - 02/2008
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2017 - 06/2010
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 01/2020
2	TOR Serine-Threonine KinasesIBA 01/2018 - 08/2009
2	Antineoplastic Agents (Antineoplastics)IBA 01/2018 - 05/2009
2	Mechanistic Target of Rapamycin Complex 2IBA 01/2018 - 07/2015
2	Proteins (Proteins, Gene)FDA Link 07/2015 - 08/2009
2	Sirolimus (Rapamycin)FDA Link 07/2015 - 08/2009
2	Tyrosine Kinase InhibitorsIBA 01/2015 - 06/2010
2	ParaffinIBA 01/2013 - 07/2009
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 09/2010 - 08/2008
2	Monoclonal AntibodiesIBA 07/2009 - 02/2003
1	A-factor (Streptomyces)IBA 01/2022
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022
1	Protons (Proton)IBA 01/2022
1	selinexorIBA 01/2022
1	tisagenlecleucelIBA 01/2022
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	Antihypertensive Agents (Antihypertensives)IBA 01/2021
1	Angiotensin Receptor AntagonistsIBA 01/2021
1	Fibroblast Growth Factor 7 FDA Link 01/2021
1	brigatinibIBA 01/2021
1	LigandsIBA 01/2021
1	Everolimus FDA Link 01/2021
1	Neuregulin-1 (Neuregulin 1)IBA 01/2021
1	NeuregulinsIBA 01/2021
1	cabozantinibIBA 01/2021
1	Losartan (Cozaar)FDA LinkGeneric 01/2021
1	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	mirdametinibIBA 01/2021
1	Tyrosine (L-Tyrosine)FDA Link 01/2021
1	CytokinesIBA 01/2021
1	dacomitinibIBA 01/2020
1	epidermal growth factor receptor VIIIIBA 01/2020
1	omipalisibIBA 01/2018
1	PanobinostatIBA 01/2018
1	CrizotinibIBA 01/2018
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2018
1	Dasatinib (BMS 354825)FDA Link 01/2018
1	EphA1 Receptor (Eph Receptor)IBA 01/2018
1	Drug CombinationsIBA 01/2018
1	Indicators and Reagents (Reagents)IBA 01/2017
1	Choline (Choline Chloride)IBA 01/2017
1	CreatineIBA 01/2017
1	Vascular Endothelial Growth Factor DIBA 10/2016
1	Dihydrotachysterol (AT 10)IBA 08/2016
1	O(6)-Methylguanine-DNA MethyltransferaseIBA 01/2016
1	MTOR InhibitorsIBA 07/2015
1	vistusertibIBA 07/2015
1	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 07/2015

Therapy/Procedure

36	Therapeutics 01/2022 - 02/2003
9	Radiotherapy 01/2022 - 07/2008
8	Drug Therapy (Chemotherapy) 01/2021 - 07/2008
4	Aftercare (After-Treatment) 01/2018 - 05/2010
1	Drug Tapering 01/2021
1	Operative Surgical Procedures 01/2021
1	Mind-Body Therapies 08/2016